AstraZeneca Annual Report and Financial Statements 88 Form 20-F Information 2003 Notes to the Financial Statements continued 25 Disposal of business operations 2003 2002 2001 $m $m $m Fixed assets 70 Current assets 34 Creditors due within one year 17 Book value of net assets disposed 87 Less: Cash included in undertakings disposed 7 Cash consideration 80 The sale consideration received is in relation to the sale of Marlow Foods Limited, which was completed on 23 May 2003.
Marlow Foods Limited results have been consolidated for the period up to disposal.
Prior to its disposal, Marlow Foods Limited contributed $6m to operating cash flows and absorbed $1m in respect of fixed capital expenditure.
There was no gain or loss on disposal.
26 Reconciliation of net cash flow to movement in net funds 2003 2002 2001 $m $m $m Decrease in cash 4 22 396 Cash outflow inflow from decrease increase in loans and short term borrowings 345 118 35 Cash outflow inflow from increase decrease in short term investments 771 806 260 Change in net funds resulting from cash flows 430 902 691 Exchange movements 82 75 47 Movement in net funds 348 977 738 Net funds at 1 January 3,844 2,867 3,605 Net funds at 31 December 3,496 3,844 2,867
